https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388339/
In this article, we review the advances in lupus nephritis urinary biomarkers. Such markers ideally should be capable of predicting early sub-clinical flares and could be used to follow response to therapy. In addition, some of these markers have been found to be involved in the pathogenesis of lupus nephritis.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11051403/
Other promising urine biomarkers—such as Angptl4, L-selectin, TPP1, and TGFβ1—also had high ROC AUC values for distinguishing patients with lupus and AR from those with iSLE, with the combination of Angptl4, L-selectin, and TPP1 yielding the highest discrimination with an AUC of 0.97 .

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917506/
With respect to lupus nephritis, however, urinary biomarkers may be more specific for kidney damage than serum biomarkers, particularly in SLE patients with active systemic disease. Furthermore, obtaining urine for laboratory testing is much easier and less invasive, making urine a more ideal biological sample for a disease that requires

https://pubmed.ncbi.nlm.nih.gov/32743523/
In this article, we review the advances in lupus nephritis urinary biomarkers. Such markers ideally should be capable of predicting early sub-clinical flares and could be used to follow response to therapy. In addition, some of these markers have been found to be involved in the pathogenesis of lupus nephritis.

https://www.nature.com/articles/s41467-020-15986-3
Emerging urinary biomarkers continue to show promise in evaluating lupus nephritis (LN). Here, we screen urine from active LN patients for 1129 proteins using an aptamer-based platform, followed

https://mdpi-res.com/d_attachment/jcm/jcm-13-02339/article_deploy/jcm-13-02339.pdf?version=1713425944
Other promising urine biomarkers—such as Angptl4, L-selectin, TPP1, and TGFβ1—also had high ROC AUC values for distinguishing patients with lupus and AR from those with iSLE, with the com-bination of Angptl4, L-selectin, and TPP1 yielding the highest discrimination with an AUC of 0.97 [56].

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0275016
Conclusions There are 10 SRs of evidence relating to the diagnostic accuracy of serum and urinary biomarkers for lupus nephritis. Among the BMs evaluated, anti-C1q, urinary MCP-1, TWEAK, and NGAL stood out, highlighting the need for additional research, especially on LN diagnostic panels, and attempting to address methodological issues within

https://pubmed.ncbi.nlm.nih.gov/34515043/
Introduction: While renal biopsy remains the gold standard for diagnosing lupus nephritis (LN), the prognostic and diagnostic role of non-invasive biomarkers for LN is currently debated. Methods: Available studies published in last 5 years (2015-2020) assessing the diagnostic and prognostic value of urinary and/or serological biomarkers in subjects with LN were analyzed in this systematic review.

https://academic.oup.com/labmed/advance-article/doi/10.1093/labmed/lmae015/7630536
Urinary Biomarkers for LN. Like blood, urine also contains a variety of components, such as epithelial cells, proteins, glucose, inorganic salts, and trace elements, which can be used as biomarkers for laboratory medicine. Arazi et al 20 used single cell transcriptomics to analyze kidney and urine samples from LN patients and healthy

https://www.mdpi.com/1422-0067/22/13/7143
Figure 1. Physiopathology of LN and urine biomarkers. Renal damage in LN is mediated by the infiltration of effector leukocytes, autoantibody binding to nuclear and non-nuclear autoantigens, and generation of IC. These IC are deposed in the glomeruli, affecting the kidney function and leading to an inflammatory cascade.

https://pubmed.ncbi.nlm.nih.gov/32976199/
Background/objective: A search for the ideal biomarker for lupus nephritis (LN) is still underway, one that can be used for early detection and correlate with the class and activity of LN. Urine is normally devoid of leukocytes; however, it has been observed that macrophages and T lymphocytes are routinely present in the urine of LN patients and those with other proliferative renal diseases.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267641/
Keywords: Lupus nephritis, urine biomarkers, non-invasive diagnosis, immune effector. Go to: 1. Introduction. Systemic lupus erythematosus is an autoimmune disease that can affect any organ of the body [ 1 ]. The kidney is one of the main organs affected by SLE, and lupus nephritis (LN) is significantly associated with an increase in the

https://www.sciencedirect.com/science/article/pii/S156899720500203X
In the case of urine biomarkers of lupus nephritis this "gold standard" could be renal biopsy scores or longer-term outcome defined as either renal death (dialysis, transplantation) or significant deterioration in renal function. Any urinary marker should be superior to existing standards (proteinuria, hematuria) but show significant

https://www.sciencedirect.com/science/article/pii/S2589909020300095
In this article, we review the advances in lupus nephritis urinary biomarkers. Such markers ideally should be capable of predicting early sub-clinical flares and could be used to follow response to therapy. In addition, some of these markers have been found to be involved in the pathogenesis of lupus nephritis. 1.

https://journals.lww.com/jclinrheum/abstract/2021/12000/urinary_cellular_profile_as_a_biomarker_for_lupus.35.aspx
re routinely present in the urine of LN patients and those with other proliferative renal diseases. This provides the idea for their potential use as biomarkers for proliferative LN. Here, we measured the urinary CD4+, CD8+ T lymphocytes, and CD14+ monocytes in patients with systemic lupus erythematosus (SLE) as potential biomarkers for LN. Methods A longitudinal case-control study included 30

https://www.uh.edu/news-events/stories/2024/january/01222024-mohan-lupus-nephritis-new-briomarkers-dna.php
By Laurie Fickman — 713-743-8454. January 22, 2024 —. Health and Medicine. Research. Share this story. New biomarkers with improved diagnostic performance for early detection of lupus nephritis have been discovered in the University of Houston lab of Chandra Mohan, a pioneer in lupus research. Early identification of renal involvement in

https://pubmed.ncbi.nlm.nih.gov/20127204/
Urinary biomarkers in lupus nephritis Clin Rev Allergy Immunol. 2011 Jun;40(3):138-50. doi: 10.1007/s12016-010-8197-z. Authors Joyce Reyes ... Since urinary biomarkers are more easily obtainable with much less risk to the patient than repeat renal biopsies, and these may more accurately discern between renal disease and other organ

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301935/
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by aberrant activity of the immune system [ 1] and presents with a wide range of clinical manifestations, including renal, dermatological, neuropsychiatric, and cardiovascular symptoms [ 2 ]. The incidence of SLE is 0.3-31.5 in 100,000 per year, and the adjusted

https://lupusnewstoday.com/news/new-biomarkers-lupus-nephritis-discovered/
In their study, the scientists aimed to identify new urinary biomarkers of lupus nephritis using a highly sensitive technique called proximity extension assay, or PEA, that can detect proteins even at very low levels. Urine samples were obtained from 87 SLE patients and 30 healthy individuals who served as controls. There were 34 patients with

https://www.kidney.org/atoz/content/lupus-nephritis
No one knows what causes the disease. Your family history and things in your environment such as infections, viruses, toxic chemicals or pollutants (car fumes, factory smoke) may play a role in causing the disease. Men and women of all ages and races get lupus. However, about 90 percent of people diagnosed with lupus are women.

https://karger.com/ajn/article/52/7/559/821292/Prognostic-and-Diagnostic-Values-of-Novel-Serum
Abstract. Introduction: While renal biopsy remains the gold standard for diagnosing lupus nephritis (LN), the prognostic and diagnostic role of non-invasive biomarkers for LN is currently debated. Methods: Available studies published in last 5 years (2015-2020) assessing the diagnostic and prognostic value of urinary and/or serological biomarkers in subjects with LN were analyzed in this

https://www.semanticscholar.org/paper/Differential-lncRNA-profiles-of-blood-exosomes-from-Peng-Ma/6643c067951c808687acef0ea33dce0e1c14b0e6
DOI: 10.1016/j.gene.2024.148713 Corpus ID: 270628317; Differential lncRNA profiles of blood plasma-derived exosomes from systemic lupus erythematosus. @article{Peng2024DifferentialLP, title={Differential lncRNA profiles of blood plasma-derived exosomes from systemic lupus erythematosus.}, author={Xin-chen Peng and Lin-li Ma and Jie-yu Miao and Sheng-qian Xu and Zong-wen Shuai}, journal={Gene

https://pubmed.ncbi.nlm.nih.gov/32892509/
Urinary Biomarkers in Lupus Nephritis: Are We There Yet? Arthritis Rheumatol. 2021 Feb;73 (2):194-196. doi: 10.1002/art.41508. Epub 2021 Jan 13.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570701/
Abstract. Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). However, promising emerging biomarkers pave the way toward an improved management of patients with LN. We have reviewed the literature over the past decade, and we herein summarise the most relevant biomarkers for

https://www.childrenscolorado.org/advances-answers/recent-articles/biomarkers-for-neuro-lupus/
Neuropsychiatric lupus may soon be easier to diagnosis. A new study found elevated levels of two blood-based biomarkers in patients with the condition. Close. Close Careers ... Fetal ultrasound and fetal MRI were compared for diagnosing congenital anomalies of the kidney and urinary tract (CAKUT). See how the findings could impact prenatal

https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03643-6
Tubular biomarkers, which reflect tubular dysfunction or injury, are associated with incident chronic kidney disease and kidney function decline. Several tubular biomarkers have also been implicated in the progression of autosomal dominant polycystic kidney disease (ADPKD). We evaluated changes in multiple tubular biomarkers in four groups of patients with ADPKD who participated in one of two

https://pubmed.ncbi.nlm.nih.gov/37698235/
Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). The aim of this study was to identify serum insulin-like growth factor binding protein-2 (IGFBP-2) as a novel non-invasive biomarker for clinical disease and renal pathology in pediatric LN.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372620/
Considering the urinary concentration of all six biomarkers, the pediatric Renal Activity Index for Lupus (RAIL) can be calculated, where a higher score reflects high renal inflammation, and the score is >90% accurate in detecting LN activity histologic activity measures (10-12). The standard operating procedures for collecting and storing